港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

百奧賽圖-B

28.000

+2.1208.19%

成交量：95.10萬

成交額：2,649.87萬

市值：111.83億

市盈率：304.58

高：28.460

開：26.000

低：26.000

收：25.880

52周最高：31.340

52周最低：5.600

股本：3.99億

香港流通股本：1.11億

量比：2.70

換手率：0.86%

股息：- -

股息率：- -

每股收益(LYR):0.092

淨資產收益率：16.11%

總資產收益率：6.20%

市淨率：11.49

市盈率(LYR):304.58

市銷率: 8.61

資料載入中...

總覽公司新聞公告

港股異動 | 百奧賽圖-B(02315)漲超3% 近日宣佈與百濟神州達成抗體分子全球許可協議

百奧賽圖-B盤中異動早盤快速拉昇5.77%報22.000港元

百奧賽圖臨牀前業務矩陣全面升級，官網煥新上線，加速全球新藥研發

美国商业资讯

百奧賽圖IPO：一場在鋼絲上的「遊走」

投资者网-思维财经

百奧賽圖科創板IPO背後：專職研發人員驟降至5人、募資額縮水

北京商报官方账号

百奧賽圖IPO：研發投入縮水、專職研發人員驟降至僅剩5人，專利待審、關聯交易等問題受關注

百奧賽圖-B盤中異動早盤快速下挫5.12%

百奧賽圖-B07月17日主力淨流入112.0萬元散户資金拋售

百奧賽圖-B盤中異動股價大跌5.20%

2025年醫保政策與產業動態：產業佈局升級與行業監管強化

百奧賽圖-B盤中異動臨近收盤股價大跌5.30%

百奧賽圖與百濟神州達成抗體分子許可協議，加速創新藥物開發

美国商业资讯

百奧賽圖-B盤中異動急速上漲5.33%

百奧賽圖IPO：18億虧損下的高管薪酬狂歡與研發斷崖

70%海外收入含金量：百奧賽圖進入全球化價值兑現期

Ofweek光电信息网

誰能為全球創新藥提供真正的「源頭動力」？

百奧賽圖-B盤中異動早盤股價大跌5.22%報21.800港元

百奧賽圖-B(02315.HK)獲LAKE BLEU CAPITAL (Hong Kong)增持8.15萬股

LAKE BLEU CAPITAL (Hong Kong) LIMITED增持百奧賽圖(02315)8.15萬股每股作價約23.39港元

智通财经网

百奧賽圖-B盤中異動快速下跌5.08%

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/02315/news?page=6"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02315","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02315\",,,,,undefined,":{"symbol":"02315","market":"HK","secType":"STK","nameCN":"百奧賽圖-B","latestPrice":28,"timestamp":1761898110948,"preClose":25.88,"halted":0,"volume":951000,"delay":0,"floatShares":110781920,"shares":399398420,"eps":0.09193080766510993,"marketStatus":"休市中","change":2.12,"latestTime":"10-31 16:08:30","open":26,"high":28.46,"low":26,"amount":26498675,"amplitude":0.095054,"askPrice":28.2,"askSize":1500,"bidPrice":28,"bidSize":10500,"shortable":0,"etf":0,"ttmEps":0.36328453715604536,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1762133400000},"marketStatusCode":7,"adr":0,"listingDate":1661961600000,"exchange":"SEHK","adjPreClose":25.88,"openAndCloseTimeList":[[1761874200000,1761883200000],[1761886800000,1761897600000]],"volumeRatio":2.70017035844127,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02315\",,,,,undefined,":{"symbol":"02315","floatShares":110781920,"roa":"6.20%","roe":"16.11%","lyrEps":0.091931,"volumeRatio":2.70017035844127,"shares":399398420,"dividePrice":0,"high":28.46,"amplitude":0.095054,"preClose":25.88,"low":26,"week52Low":5.6,"pbRate":"11.49","psRate":"8.61","week52High":31.34,"institutionHeld":0,"latestPrice":28,"committee":0.75,"eps":0.09193080766510993,"divideRate":0,"volume":951000,"delay":0,"ttmEps":0.36328453715604536,"open":26,"prevYearClose":8.5,"prevWeekClose":22.94,"prevMonthClose":28,"prevQuarterClose":28.48,"fiveDayClose":23.4,"twentyDayClose":28.48,"sixtyDayClose":26.8},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02315\",params:#limit:5,,,undefined,":[{"date":"2025-08-28","symbol":"02315","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756344600000,"name":null,"time":"","dateTimestamp":1756310400000,"actualEps":null},{"date":"2025-03-26","symbol":"02315","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1742952600000,"name":null,"time":"盤後","dateTimestamp":1742918400000,"actualEps":null},{"market":"HK","date":"2024-08-28","symbol":"02315","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1724774400000,"reportTimeType":"post","actualEps":null},{"date":"2024-03-27","symbol":"02315","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1711503000000,"name":null,"time":"","dateTimestamp":1711468800000,"actualEps":null},{"date":"2023-08-28","symbol":"02315","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1693186200000,"name":null,"time":"","dateTimestamp":1693152000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02315\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02315\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":1,"buy":0,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":1,"analysts":1,"updateTime":1743436800000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02315\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02315","date":"2025-10-30","current":77.074571,"percent":0.847044,"low":-25.760101,"twenty":-15.085241,"median":-9.290433,"eighty":-5.76873,"high":292.060693,"avg":21.753107,"sd":76.184694,"marketCap":10336431109},"quantilePoints":[{"date":"2022-09-02","current":-17.320141,"twenty":-17.183465,"median":-16.97845,"eighty":-16.773436,"marketCap":10750256182},{"date":"2022-09-09","current":-16.423987,"twenty":-16.725792,"median":-16.549247,"eighty":-16.380597,"marketCap":10155223552},{"date":"2022-09-16","current":-16.318147,"twenty":-16.63676,"median":-16.36975,"eighty":-16.316556,"marketCap":9996548184},{"date":"2022-09-23","current":-16.637534,"twenty":-16.675139,"median":-16.58177,"eighty":-16.318147,"marketCap":9996548184},{"date":"2022-09-30","current":-16.676297,"twenty":-16.685959,"median":-16.63676,"eighty":-16.318147,"marketCap":10464238604},{"date":"2022-10-07","current":-16.709082,"twenty":-16.759103,"median":-16.644605,"eighty":-16.32635,"marketCap":10484208525},{"date":"2022-10-14","current":-17.016883,"twenty":-16.759103,"median":-16.64107,"eighty":-16.343742,"marketCap":10564088209},{"date":"2022-10-21","current":-17.166611,"twenty":-17.031627,"median":-16.675139,"eighty":-16.354867,"marketCap":10584058130},{"date":"2022-10-28","current":-16.904053,"twenty":-17.031627,"median":-16.675441,"eighty":-16.36536,"marketCap":10404328841},{"date":"2022-11-04","current":-16.612618,"twenty":-17.082341,"median":-16.676297,"eighty":-16.369306,"marketCap":10324449157},{"date":"2022-11-11","current":-16.306635,"twenty":-17.029879,"median":-16.67602,"eighty":-16.36536,"marketCap":10224599552},{"date":"2022-11-18","current":-16.746191,"twenty":-17.082341,"median":-16.685959,"eighty":-16.369306,"marketCap":10464238604},{"date":"2022-11-25","current":-16.976752,"twenty":-17.082341,"median":-16.684366,"eighty":-16.41314,"marketCap":10524148367},{"date":"2022-12-02","current":-16.467053,"twenty":-17.08023,"median":-16.682773,"eighty":-16.455087,"marketCap":10384358920},{"date":"2022-12-09","current":-16.284129,"twenty":-17.029868,"median":-16.675441,"eighty":-16.360668,"marketCap":10364388999},{"date":"2022-12-16","current":-16.102056,"twenty":-17.016962,"median":-16.650632,"eighty":-16.338699,"marketCap":10224599552},{"date":"2022-12-23","current":-16.065604,"twenty":-16.984778,"median":-16.637147,"eighty":-16.314572,"marketCap":10204629631},{"date":"2022-12-30","current":-15.934887,"twenty":-16.966494,"median":-16.614292,"eighty":-16.270012,"marketCap":10244569473},{"date":"2023-01-06","current":-15.64986,"twenty":-16.949062,"median":-16.590059,"eighty":-16.212217,"marketCap":10164689789},{"date":"2023-01-13","current":-15.537191,"twenty":-16.938757,"median":-16.549025,"eighty":-16.179981,"marketCap":10284509315},{"date":"2023-01-20","current":-15.580379,"twenty":-16.925026,"median":-16.534664,"eighty":-16.156179,"marketCap":10224599552},{"date":"2023-01-27","current":-15.546768,"twenty":-16.914539,"median":-16.533948,"eighty":-16.10098,"marketCap":10204629631},{"date":"2023-02-03","current":-15.436408,"twenty":-16.898489,"median":-16.443424,"eighty":-15.899534,"marketCap":10184659710},{"date":"2023-02-10","current":-15.407922,"twenty":-16.85946,"median":-16.367528,"eighty":-15.72674,"marketCap":10104780026},{"date":"2023-02-17","current":-15.462828,"twenty":-16.826005,"median":-16.357582,"eighty":-15.576487,"marketCap":10044870263},{"date":"2023-02-24","current":-15.747577,"twenty":-16.809749,"median":-16.341273,"eighty":-15.581234,"marketCap":10104780026},{"date":"2023-03-03","current":-16.543432,"twenty":-16.800921,"median":-16.334837,"eighty":-15.597252,"marketCap":10683907735},{"date":"2023-03-10","current":-15.544967,"twenty":-15.579303,"median":-15.560593,"eighty":-15.545027,"marketCap":9964990579},{"date":"2023-03-17","current":-15.303442,"twenty":-16.772422,"median":-16.316556,"eighty":-15.545905,"marketCap":9905080816},{"date":"2023-03-24","current":-15.373763,"twenty":-16.756627,"median":-16.272365,"eighty":-15.544864,"marketCap":10064840184},{"date":"2023-03-31","current":-14.490947,"twenty":-16.750261,"median":-16.244078,"eighty":-15.503171,"marketCap":9964990579},{"date":"2023-04-06","current":-14.616535,"twenty":-16.74805,"median":-16.201654,"eighty":-15.47105,"marketCap":10044870263},{"date":"2023-04-14","current":-14.718236,"twenty":-16.746563,"median":-16.189978,"eighty":-15.435882,"marketCap":10124749947},{"date":"2023-04-21","current":-14.522496,"twenty":-16.716504,"median":-16.166943,"eighty":-15.404922,"marketCap":9984960500},{"date":"2023-04-28","current":-14.543652,"twenty":-16.690584,"median":-16.159298,"eighty":-15.375204,"marketCap":9925050737},{"date":"2023-05-05","current":-14.549057,"twenty":-16.684047,"median":-16.100712,"eighty":-15.342097,"marketCap":9945020658},{"date":"2023-05-12","current":-14.620521,"twenty":-16.678887,"median":-16.039544,"eighty":-15.333905,"marketCap":9925050737},{"date":"2023-05-19","current":-14.943491,"twenty":-16.675965,"median":-15.890696,"eighty":-15.23178,"marketCap":9725351527},{"date":"2023-05-25","current":-14.912803,"twenty":-16.675501,"median":-15.809962,"eighty":-15.067549,"marketCap":9665441764},{"date":"2023-06-02","current":-14.437965,"twenty":-16.668929,"median":-15.747577,"eighty":-14.987375,"marketCap":9325953107},{"date":"2023-06-09","current":-14.613629,"twenty":-16.656022,"median":-15.667464,"eighty":-14.759824,"marketCap":9425802712},{"date":"2023-06-16","current":-13.688431,"twenty":-16.648221,"median":-15.639948,"eighty":-14.693346,"marketCap":8786765240},{"date":"2023-06-23","current":-13.012764,"twenty":-16.643191,"median":-15.607551,"eighty":-14.659979,"marketCap":8307487136},{"date":"2023-06-30","current":-13.257814,"twenty":-16.637379,"median":-15.582942,"eighty":-14.61421,"marketCap":8387366820},{"date":"2023-07-07","current":-12.682797,"twenty":-16.632266,"median":-15.576118,"eighty":-14.550185,"marketCap":8007938321},{"date":"2023-07-14","current":-12.819193,"twenty":-16.613957,"median":-15.551683,"eighty":-14.529885,"marketCap":8207637531},{"date":"2023-07-21","current":-12.973057,"twenty":-16.608106,"median":-15.545068,"eighty":-14.516129,"marketCap":8267547294},{"date":"2023-07-28","current":-12.535237,"twenty":-16.582609,"median":-15.540993,"eighty":-14.488236,"marketCap":7979980431},{"date":"2023-08-04","current":-11.938194,"twenty":-16.552097,"median":-15.522734,"eighty":-14.412097,"marketCap":7612533885},{"date":"2023-08-11","current":-10.431222,"twenty":-16.549158,"median":-15.479965,"eighty":-14.353579,"marketCap":6614037835},{"date":"2023-08-18","current":-9.656286,"twenty":-16.54773,"median":-15.439162,"eighty":-14.141185,"marketCap":6078843952},{"date":"2023-08-25","current":-10.146146,"twenty":-16.543346,"median":-15.430512,"eighty":-13.53248,"marketCap":6390374720},{"date":"2023-09-01","current":-12.99564,"twenty":-16.541336,"median":-15.407922,"eighty":-13.291047,"marketCap":7293015149},{"date":"2023-09-08","current":-12.315048,"twenty":-16.534521,"median":-15.387742,"eighty":-12.99529,"marketCap":6829712982},{"date":"2023-09-15","current":-10.219312,"twenty":-16.520569,"median":-15.373763,"eighty":-12.96537,"marketCap":5711397406},{"date":"2023-09-22","current":-10.063213,"twenty":-16.466215,"median":-15.341727,"eighty":-12.868104,"marketCap":5599565848},{"date":"2023-09-29","current":-11.178127,"twenty":-16.455087,"median":-15.334187,"eighty":-12.79424,"marketCap":6230615352},{"date":"2023-10-06","current":-9.993446,"twenty":-16.423987,"median":-15.333905,"eighty":-12.692866,"marketCap":5567613974},{"date":"2023-10-13","current":-9.290433,"twenty":-16.36975,"median":-15.303888,"eighty":-12.547785,"marketCap":5168215554},{"date":"2023-10-20","current":-8.010443,"twenty":-16.367528,"median":-15.102694,"eighty":-12.48935,"marketCap":4449298398},{"date":"2023-10-27","current":-8.488672,"twenty":-16.362478,"median":-15.063511,"eighty":-12.292711,"marketCap":4712901356},{"date":"2023-11-03","current":-8.710133,"twenty":-16.359022,"median":-15.056757,"eighty":-12.104621,"marketCap":4848696818},{"date":"2023-11-10","current":-8.898536,"twenty":-16.357046,"median":-14.912803,"eighty":-11.941145,"marketCap":4952540408},{"date":"2023-11-17","current":-8.747876,"twenty":-16.349399,"median":-14.761097,"eighty":-11.58475,"marketCap":4912600566},{"date":"2023-11-24","current":-9.071472,"twenty":-16.342534,"median":-14.718236,"eighty":-10.82373,"marketCap":5136263681},{"date":"2023-12-01","current":-8.640618,"twenty":-16.330975,"median":-14.677453,"eighty":-10.271499,"marketCap":4912600566},{"date":"2023-12-08","current":-7.758741,"twenty":-16.322161,"median":-14.658546,"eighty":-10.157974,"marketCap":4393382620},{"date":"2023-12-15","current":-7.349523,"twenty":-16.318638,"median":-14.616817,"eighty":-10.062883,"marketCap":4185695441},{"date":"2023-12-22","current":-8.126371,"twenty":-16.317676,"median":-14.584545,"eighty":-9.957278,"marketCap":4625033703},{"date":"2023-12-29","current":-8.362487,"twenty":-16.317157,"median":-14.562072,"eighty":-9.871741,"marketCap":4784793071},{"date":"2024-01-05","current":-7.803247,"twenty":-16.314572,"median":-14.547516,"eighty":-9.761569,"marketCap":4433322462},{"date":"2024-01-12","current":-7.461837,"twenty":-16.302134,"median":-14.536365,"eighty":-9.504477,"marketCap":4241611220},{"date":"2024-01-19","current":-7.035876,"twenty":-16.279423,"median":-14.522365,"eighty":-9.33176,"marketCap":3993984200},{"date":"2024-01-26","current":-6.794958,"twenty":-16.258464,"median":-14.515165,"eighty":-9.235745,"marketCap":3842212800},{"date":"2024-02-02","current":-6.280276,"twenty":-16.248749,"median":-14.494808,"eighty":-9.119832,"marketCap":3546657969},{"date":"2024-02-09","current":-6.080594,"twenty":-16.236113,"median":-14.46742,"eighty":-9.04289,"marketCap":3450802348},{"date":"2024-02-16","current":-6.100388,"twenty":-16.212217,"median":-14.448798,"eighty":-8.990936,"marketCap":3462784301},{"date":"2024-02-23","current":-5.580985,"twenty":-16.200095,"median":-14.377271,"eighty":-8.779882,"marketCap":3151253533},{"date":"2024-03-01","current":-6.821664,"twenty":-16.194567,"median":-14.359409,"eighty":-8.66879,"marketCap":3854194753},{"date":"2024-03-08","current":-6.691446,"twenty":-16.187898,"median":-14.283383,"eighty":-8.531038,"marketCap":3782303037},{"date":"2024-03-15","current":-7.256077,"twenty":-16.179981,"median":-13.930623,"eighty":-8.39945,"marketCap":4097827789},{"date":"2024-03-22","current":-6.151369,"twenty":-16.169224,"median":-13.579636,"eighty":-8.326104,"marketCap":3470772269},{"date":"2024-03-28","current":-8.333872,"twenty":-16.165922,"median":-13.45297,"eighty":-8.269405,"marketCap":3454796333},{"date":"2024-04-05","current":-6.804027,"twenty":-16.165092,"median":-13.428292,"eighty":-8.136639,"marketCap":2819752845},{"date":"2024-04-12","current":-6.357095,"twenty":-16.162416,"median":-13.25289,"eighty":-8.013058,"marketCap":2636029572},{"date":"2024-04-19","current":-7.133743,"twenty":-16.143691,"median":-12.995421,"eighty":-7.920902,"marketCap":2955548308},{"date":"2024-04-26","current":-8.011238,"twenty":-16.101518,"median":-12.982283,"eighty":-7.901825,"marketCap":3315006886},{"date":"2024-05-03","current":-8.4804,"twenty":-16.099367,"median":-12.963448,"eighty":-7.90259,"marketCap":3506718127},{"date":"2024-05-10","current":-9.394996,"twenty":-16.065604,"median":-12.898932,"eighty":-7.913843,"marketCap":3894134595},{"date":"2024-05-17","current":-9.215805,"twenty":-16.044756,"median":-12.867532,"eighty":-7.919339,"marketCap":3814254911},{"date":"2024-05-24","current":-9.246573,"twenty":-15.983649,"median":-12.819193,"eighty":-7.921471,"marketCap":3818248895},{"date":"2024-05-31","current":-8.589796,"twenty":-15.941845,"median":-12.752108,"eighty":-7.961158,"marketCap":3550651953},{"date":"2024-06-07","current":-7.768472,"twenty":-15.864181,"median":-12.691034,"eighty":-7.961158,"marketCap":3207169312},{"date":"2024-06-14","current":-7.814329,"twenty":-15.826431,"median":-12.62649,"eighty":-7.909342,"marketCap":3223145249},{"date":"2024-06-21","current":-7.277623,"twenty":-15.809345,"median":-12.53142,"eighty":-7.79631,"marketCap":2995488150},{"date":"2024-06-28","current":-7.426256,"twenty":-15.789546,"median":-12.48935,"eighty":-7.753383,"marketCap":3055397913},{"date":"2024-07-05","current":-7.495836,"twenty":-15.765827,"median":-12.315048,"eighty":-7.684126,"marketCap":3083355802},{"date":"2024-07-12","current":-7.223066,"twenty":-15.726554,"median":-12.278434,"eighty":-7.629416,"marketCap":2975518229},{"date":"2024-07-19","current":-7.193846,"twenty":-15.685816,"median":-12.106939,"eighty":-7.601973,"marketCap":2963536276},{"date":"2024-07-26","current":-6.703571,"twenty":-15.668373,"median":-11.984006,"eighty":-7.505156,"marketCap":2771825034},{"date":"2024-08-02","current":-6.523845,"twenty":-15.657694,"median":-11.938194,"eighty":-7.459727,"marketCap":2695939335},{"date":"2024-08-09","current":-5.9622,"twenty":-15.645895,"median":-11.636139,"eighty":-7.412301,"marketCap":2480264188},{"date":"2024-08-16","current":-6.420552,"twenty":-15.638291,"median":-11.199705,"eighty":-7.36919,"marketCap":2671975429},{"date":"2024-08-23","current":-6.211949,"twenty":-15.624504,"median":-10.786048,"eighty":-7.29332,"marketCap":2596089730},{"date":"2024-08-30","current":-9.587395,"twenty":-15.607156,"median":-10.431222,"eighty":-7.274264,"marketCap":2568131840},{"date":"2024-09-06","current":-9.344329,"twenty":-15.59757,"median":-10.232292,"eighty":-7.282379,"marketCap":2504228093},{"date":"2024-09-13","current":-8.935525,"twenty":-15.58317,"median":-10.160931,"eighty":-7.29332,"marketCap":2388402551},{"date":"2024-09-20","current":-9.357565,"twenty":-15.581519,"median":-10.098938,"eighty":-7.308194,"marketCap":2516210046},{"date":"2024-09-27","current":-10.320372,"twenty":-15.579527,"median":-10.073832,"eighty":-7.345779,"marketCap":2791794955},{"date":"2024-10-04","current":-14.698364,"twenty":-15.576118,"median":-10.122542,"eighty":-7.349523,"marketCap":3958038342},{"date":"2024-10-10","current":-11.132217,"twenty":-15.571743,"median":-10.161683,"eighty":-7.362761,"marketCap":2979512213},{"date":"2024-10-18","current":-10.459714,"twenty":-15.559408,"median":-10.219312,"eighty":-7.372309,"marketCap":2783806987},{"date":"2024-10-25","current":-10.340316,"twenty":-15.548734,"median":-10.261664,"eighty":-7.392688,"marketCap":2751855113},{"date":"2024-11-01","current":-9.358506,"twenty":-15.545617,"median":-10.176873,"eighty":-7.401158,"marketCap":2492246140},{"date":"2024-11-08","current":-9.082377,"twenty":-15.54512,"median":-10.153538,"eighty":-7.405713,"marketCap":2400384504},{"date":"2024-11-15","current":-9.288588,"twenty":-15.544987,"median":-10.084452,"eighty":-7.417986,"marketCap":2436330362},{"date":"2024-11-22","current":-8.63879,"twenty":-15.54483,"median":-10.062389,"eighty":-7.42517,"marketCap":2264589041},{"date":"2024-11-29","current":-8.902865,"twenty":-15.538712,"median":-9.993446,"eighty":-7.43744,"marketCap":2332486772},{"date":"2024-12-06","current":-9.336462,"twenty":-15.534727,"median":-9.926941,"eighty":-7.454703,"marketCap":2440324346},{"date":"2024-12-13","current":-12.12859,"twenty":-15.525009,"median":-9.993446,"eighty":-7.461134,"marketCap":3167229470},{"date":"2024-12-20","current":-12.949109,"twenty":-15.49665,"median":-10.062389,"eighty":-7.463103,"marketCap":3362934696},{"date":"2024-12-27","current":-13.005336,"twenty":-15.48963,"median":-10.080954,"eighty":-7.464331,"marketCap":3374916649},{"date":"2025-01-03","current":-12.469835,"twenty":-15.485315,"median":-10.098938,"eighty":-7.471726,"marketCap":3239121186},{"date":"2025-01-10","current":-11.884455,"twenty":-15.469406,"median":-10.153538,"eighty":-7.500496,"marketCap":3075367834},{"date":"2025-01-17","current":-11.658965,"twenty":-15.458095,"median":-10.176873,"eighty":-7.522658,"marketCap":3019452055},{"date":"2025-01-24","current":-12.076794,"twenty":-15.438611,"median":-10.261664,"eighty":-7.541025,"marketCap":3147259549},{"date":"2025-01-28","current":-12.004152,"twenty":-15.43751,"median":-10.281809,"eighty":-7.549574,"marketCap":3143265565},{"date":"2025-02-07","current":-11.806203,"twenty":-15.434831,"median":-10.340316,"eighty":-7.578575,"marketCap":3075367834},{"date":"2025-02-14","current":-12.541461,"twenty":-15.429859,"median":-10.454096,"eighty":-7.606855,"marketCap":3259091107},{"date":"2025-02-21","current":-13.329047,"twenty":-15.417717,"median":-10.628219,"eighty":-7.62064,"marketCap":3482754222},{"date":"2025-02-28","current":-14.093919,"twenty":-15.409299,"median":-10.676284,"eighty":-7.632465,"marketCap":3670471479},{"date":"2025-03-07","current":-18.299233,"twenty":-15.417717,"median":-10.848852,"eighty":-7.647988,"marketCap":4784793071},{"date":"2025-03-14","current":-20.796737,"twenty":-15.448628,"median":-11.155172,"eighty":-7.670492,"marketCap":5439806480},{"date":"2025-03-21","current":-24.073812,"twenty":-15.503171,"median":-11.213505,"eighty":-7.682665,"marketCap":6294519099},{"date":"2025-03-28","current":166.890984,"twenty":-15.535343,"median":-11.265741,"eighty":-7.670492,"marketCap":5990976300},{"date":"2025-04-03","current":148.592565,"twenty":-15.52956,"median":-11.188916,"eighty":-7.619299,"marketCap":5335962891},{"date":"2025-04-11","current":137.813994,"twenty":-15.509692,"median":-11.08181,"eighty":-7.526181,"marketCap":4904612597},{"date":"2025-04-17","current":132.251881,"twenty":-15.489879,"median":-10.723244,"eighty":-7.463876,"marketCap":4712901356},{"date":"2025-04-25","current":130.653866,"twenty":-15.488881,"median":-10.665186,"eighty":-7.440236,"marketCap":4664973545},{"date":"2025-05-02","current":155.157263,"twenty":-15.474616,"median":-10.628219,"eighty":-7.405713,"marketCap":5551638038},{"date":"2025-05-09","current":134.566778,"twenty":-15.466117,"median":-10.459714,"eighty":-7.370749,"marketCap":4848696818},{"date":"2025-05-16","current":132.156923,"twenty":-15.448628,"median":-10.385769,"eighty":-7.295224,"marketCap":4800769008},{"date":"2025-05-23","current":176.26836,"twenty":-15.43751,"median":-10.285563,"eighty":-7.262732,"marketCap":6422326593},{"date":"2025-05-30","current":194.268841,"twenty":-15.434831,"median":-10.232292,"eighty":-7.240227,"marketCap":7109291876},{"date":"2025-06-06","current":190.508609,"twenty":-15.429859,"median":-10.162435,"eighty":-7.194033,"marketCap":6989472350},{"date":"2025-06-13","current":242.122352,"twenty":-15.417717,"median":-10.132322,"eighty":-7.161917,"marketCap":8886614845},{"date":"2025-06-20","current":239.872041,"twenty":-15.409299,"median":-10.084452,"eighty":-7.088113,"marketCap":8786765240},{"date":"2025-06-27","current":246.269522,"twenty":-15.398923,"median":-10.062389,"eighty":-7.044514,"marketCap":9046374213},{"date":"2025-07-04","current":250.063256,"twenty":-15.391199,"median":-10.003136,"eighty":-7.007459,"marketCap":9186163660},{"date":"2025-07-11","current":230.181341,"twenty":-15.387916,"median":-9.934047,"eighty":-6.832291,"marketCap":8447276583},{"date":"2025-07-18","current":234.173998,"twenty":-15.382348,"median":-9.913676,"eighty":-6.798586,"marketCap":8587066030},{"date":"2025-07-25","current":225.72884,"twenty":-15.374844,"median":-9.853307,"eighty":-6.692805,"marketCap":8307487136},{"date":"2025-08-01","current":277.909452,"twenty":-15.373763,"median":-9.815898,"eighty":-6.59652,"marketCap":10164689789},{"date":"2025-08-08","current":261.421777,"twenty":-15.361688,"median":-9.735143,"eighty":-6.513228,"marketCap":9585562080},{"date":"2025-08-15","current":268.795789,"twenty":-15.342097,"median":-9.631387,"eighty":-6.417235,"marketCap":9841177068},{"date":"2025-08-22","current":273.580909,"twenty":-15.337645,"median":-9.532105,"eighty":-6.350598,"marketCap":9984960500},{"date":"2025-08-29","current":62.555475,"twenty":-15.334252,"median":-9.483572,"eighty":-6.272638,"marketCap":9042380228},{"date":"2025-09-05","current":69.200112,"twenty":-15.334074,"median":-9.453998,"eighty":-6.171457,"marketCap":9992948468},{"date":"2025-09-12","current":63.498906,"twenty":-15.333905,"median":-9.423977,"eighty":-6.10359,"marketCap":9186163660},{"date":"2025-09-19","current":75.976522,"twenty":-15.323094,"median":-9.37227,"eighty":-6.060838,"marketCap":10983456550},{"date":"2025-09-26","current":79.221129,"twenty":-15.305861,"median":-9.358035,"eighty":-6.019236,"marketCap":11422794812},{"date":"2025-10-03","current":75.937529,"twenty":-15.304156,"median":-9.345758,"eighty":-5.969828,"marketCap":10975468581},{"date":"2025-10-10","current":69.406568,"twenty":-15.303442,"median":-9.33177,"eighty":-5.941754,"marketCap":10016912373},{"date":"2025-10-17","current":63.035254,"twenty":-15.124286,"median":-9.321633,"eighty":-5.913943,"marketCap":9090308039},{"date":"2025-10-24","current":63.51068,"twenty":-15.102694,"median":-9.301234,"eighty":-5.842716,"marketCap":9162199754},{"date":"2025-10-30","current":71.543526,"twenty":-15.085241,"median":-9.290433,"eighty":-5.76873,"marketCap":10336431109}],"updateTime":1761941585003},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02315\",pageSize:20,pageCount:6,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2554476027","title":"港股異動 | 百奧賽圖-B(02315)漲超3% 近日宣佈與百濟神州達成抗體分子全球許可協議","url":"https://stock-news.laohu8.com/highlight/detail?id=2554476027","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554476027?lang=zh_tw&edition=fundamental","pubTime":"2025-07-28 11:20","pubTimestamp":1753672815,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，百奥赛图-B涨超3%，截至发稿，涨2.64%，报21.35港元，成交额450.75万港元。消息面上，近日，据百奥赛图官微消息，公司宣布与全球肿瘤治疗创新公司百济神州达成抗体分子的全球许可协议。根据协议条款，百济神州将向百奥赛图支付首付款。据介绍，百济神州此前已获得百奥赛图RenMice全人抗体平台的授权使用许可，本次双方在已建立的良好合作基础上进一步将合作拓展至抗体分子授权许可领域，标志着双方合作的持续深化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1322457.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2328871848.SGD","LU1969619763.USD","LU0588546209.SGD","BK0239","BK4139","BK1161","LU0307460666.USD","BK1588","ONC","BK1583","06160","688235","BK4526","BK1500","02315"],"gpt_icon":0},{"id":"2554747218","title":"百奧賽圖-B盤中異動 早盤快速拉昇5.77%報22.000港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2554747218","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554747218?lang=zh_tw&edition=fundamental","pubTime":"2025-07-28 10:08","pubTimestamp":1753668495,"startTime":"0","endTime":"0","summary":"2025年07月28日早盘10时08分，百奥赛图-B股票出现波动，股价急速上涨5.77%。截至发稿，该股报22.000港元/股，成交量8.25万股，换手率0.07%，振幅6.25%。百奥赛图-B股票所在的生物技术行业中，整体涨幅为0.53%。2023年，百奥赛图申请科创板上市获受理。根据招股书，截至本次IPO申报前，沈月雷为员工股权激励平台实缴出资以吸引优秀人才和维持团队稳定，以个人名义对外借款。同期，公司研发费用4.74亿元，同比下降32.3%，并表示“大规模研发投入阶段结束”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250728100817a6c4ee25&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250728100817a6c4ee25&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02315"],"gpt_icon":0},{"id":"2554725049","title":"百奧賽圖臨牀前業務矩陣全面升級，官網煥新上線，加速全球新藥研發","url":"https://stock-news.laohu8.com/highlight/detail?id=2554725049","media":"美国商业资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554725049?lang=zh_tw&edition=fundamental","pubTime":"2025-07-28 07:00","pubTimestamp":1753657200,"startTime":"0","endTime":"0","summary":"-- 百奥赛图，一家创新技术驱动新药研发的国际性生物技术公司，今日宣布，其临床前业务板块实现全面升级，涵盖靶点人源化小鼠、免疫系统人源化小鼠、转基因小鼠、免疫缺陷鼠等模式动物产品，并提供覆盖药效学、PK/PD、生物标志物、非GLP毒理学评估在内的一体化临床前产品及服务，为全球药物研发提供更精准、高效的解决方案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250728150106a46721be&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250728150106a46721be&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02315","BK1161"],"gpt_icon":0},{"id":"2554699712","title":"百奧賽圖IPO：一場在鋼絲上的「遊走」","url":"https://stock-news.laohu8.com/highlight/detail?id=2554699712","media":"投资者网-思维财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554699712?lang=zh_tw&edition=fundamental","pubTime":"2025-07-27 08:02","pubTimestamp":1753574576,"startTime":"0","endTime":"0","summary":"作者｜蔡俊百奥赛图的IPO之路，漫长且复杂。01游走在“钢丝”边缘2023年，百奥赛图申请科创板上市获受理。根据招股书，截至本次IPO申报前，沈月雷为员工股权激励平台实缴出资以吸引优秀人才和维持团队稳定，以个人名义对外借款。因此，眼下的科创板IPO对公司及实控人而言，资金补流的意义重大。03陷入专利纠纷百奥赛图的研发含金量，还遭到了同行的挑战。今年6月，国家知识产权局作出决定，维持涉案专利的专利权有效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250727081116a4653025&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250727081116a4653025&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02315"],"gpt_icon":0},{"id":"2553000822","title":"百奧賽圖科創板IPO背後：專職研發人員驟降至5人、募資額縮水","url":"https://stock-news.laohu8.com/highlight/detail?id=2553000822","media":"北京商报官方账号","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553000822?lang=zh_tw&edition=fundamental","pubTime":"2025-07-24 20:00","pubTimestamp":1753358411,"startTime":"0","endTime":"0","summary":"据了解，除子公司祐和医药作为公司内部的临床药物研发平台单独设置了研发部门外，百奥赛图未设置专门研发部门；公司将从事研发项目工时占比高于50%的人员认定为研发人员。在问询回复中，百奥赛图披露了报告期内公司专职和兼职研发人员数量。百奥赛图表示，报告期各期，从业务类型划分，公司创新药研发业务研发人员100%均为专职研发人员，临床前CRO业务研发人员100%均为兼职研发人员，符合创新药以及CRO的行业惯例。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724200236a4614842&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724200236a4614842&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02315","BK1161"],"gpt_icon":0},{"id":"2553256970","title":"百奧賽圖IPO：研發投入縮水、專職研發人員驟降至僅剩5人，專利待審、關聯交易等問題受關注","url":"https://stock-news.laohu8.com/highlight/detail?id=2553256970","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553256970?lang=zh_tw&edition=fundamental","pubTime":"2025-07-22 20:53","pubTimestamp":1753188807,"startTime":"0","endTime":"0","summary":"然而，此后两年百奥赛图的研发投入持续“缩水”：2023年降至4.84亿元，2024年进一步压缩至3.24亿元，占比回落至33.04%。令人担忧的是，专职研发人员数量从2022年的58人骤降至2024年的5人，占总人数比例从9.25%跌至1.48%。离职高管牵线，三年关联交易“纠缠”在百奥赛图的问询函环节中，除了研发投入情况备受关注外，公司的抗体开发业务关联交易问题同样成了监管关注的重点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722210751954cf775&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722210751954cf775&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09939","BK1515","BK1574","02315","BK1161"],"gpt_icon":0},{"id":"2553773447","title":"百奧賽圖-B盤中異動 早盤快速下挫5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2553773447","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553773447?lang=zh_tw&edition=fundamental","pubTime":"2025-07-21 09:58","pubTimestamp":1753063098,"startTime":"0","endTime":"0","summary":"2025年07月21日早盘09时58分，百奥赛图-B股票出现异动，股价快速下跌5.12%。截至发稿，该股报20.400港元/股，成交量2.05万股，换手率0.02%，振幅5.58%。机构评级方面，在所有1家参与评级的机构中，100%的券商给予卖出建议，无券商给予买入、持有建议。百奥赛图-B股票所在的生物技术行业中，整体跌幅为2.79%。百奥赛图-B公司简介：北京百奥赛图基因生物技术有限公司是一家主要从事药物开发业务及临床前研究中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250721095818954a3a07&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250721095818954a3a07&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02315","BK1161"],"gpt_icon":0},{"id":"2552743553","title":"百奧賽圖-B07月17日主力淨流入112.0萬元 散户資金拋售","url":"https://stock-news.laohu8.com/highlight/detail?id=2552743553","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552743553?lang=zh_tw&edition=fundamental","pubTime":"2025-07-17 16:15","pubTimestamp":1752740145,"startTime":"0","endTime":"0","summary":"07月17日, 百奥赛图-B股价涨1.87%，报收21.75元，成交金额823.9万元，换手率0.35%，振幅7.49%，量比1.42。百奥赛图-B今日主力资金净流入112.0万元，上一交易日主力净流出0万元。该股近5个交易日上涨3.33%，主力资金累计净流入29.1万元；近20日主力资金累计净流出107.7万元，其中净流出天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717171615a450b56b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717171615a450b56b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02315"],"gpt_icon":0},{"id":"2551979202","title":"百奧賽圖-B盤中異動 股價大跌5.20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2551979202","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551979202?lang=zh_tw&edition=fundamental","pubTime":"2025-07-14 13:28","pubTimestamp":1752470892,"startTime":"0","endTime":"0","summary":"2025年07月14日下午盘13时28分，百奥赛图-B股票出现波动，股价快速下挫5.20%。截至发稿，该股报20.050港元/股，成交量16.05万股，换手率0.14%，振幅6.62%。百奥赛图-B股票所在的生物技术行业中，整体跌幅为1.25%。百奥赛图-B公司简介：北京百奥赛图基因生物技术有限公司是一家主要从事药物开发业务及临床前研究中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714132813a44907fc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714132813a44907fc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02315"],"gpt_icon":0},{"id":"2551130912","title":"2025年醫保政策與產業動態：產業佈局升級與行業監管強化","url":"https://stock-news.laohu8.com/highlight/detail?id=2551130912","media":"报告大厅","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551130912?lang=zh_tw&edition=fundamental","pubTime":"2025-07-13 08:05","pubTimestamp":1752365100,"startTime":"0","endTime":"0","summary":"中国报告大厅网讯，随着国家医疗保障体系的不断完善，2025年医保相关政策及医药产业发展呈现显著变化。国家医保局、药监局等机构通过政策引导与严格监管，进一步优化药品供给结构，并强化了对违法违规行为的打击力度。数据显示，2025年目录调整将直接影响超万种药品的市场准入资格。总结2025年医保政策与产业布局呈现多维度深化态势：目录动态调整优化资源配置、监管强化保障行业规范、资本助力推动技术创新。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071308112797a3ed86&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071308112797a3ed86&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02315","06160","688235","BK0239","ONC"],"gpt_icon":0},{"id":"2550961135","title":"百奧賽圖-B盤中異動 臨近收盤股價大跌5.30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2550961135","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550961135?lang=zh_tw&edition=fundamental","pubTime":"2025-07-10 15:50","pubTimestamp":1752133819,"startTime":"0","endTime":"0","summary":"2025年07月10日临近收盘15时50分，百奥赛图-B股票出现波动，股价急速跳水5.30%。截至发稿，该股报20.550港元/股，成交量25.4万股，换手率0.23%，振幅7.60%。百奥赛图-B股票所在的生物技术行业中，整体跌幅为0.33%。百奥赛图-B公司简介：北京百奥赛图基因生物技术有限公司是一家主要从事药物开发业务及临床前研究中国公司。2024年，当百奥赛图在财报中高调宣布“阶段性扭亏为盈”时，董事长沈月雷的薪酬从205万元飙升至425.9万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071015502097a0ad8d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071015502097a0ad8d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02315","BK1161"],"gpt_icon":0},{"id":"2550661203","title":"百奧賽圖與百濟神州達成抗體分子許可協議，加速創新藥物開發","url":"https://stock-news.laohu8.com/highlight/detail?id=2550661203","media":"美国商业资讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550661203?lang=zh_tw&edition=fundamental","pubTime":"2025-07-10 00:00","pubTimestamp":1752076800,"startTime":"0","endTime":"0","summary":"-- 百奥赛图，一家创新技术驱动新药研发的国际性生物技术公司，今日宣布与全球肿瘤治疗创新公司百济神州达成抗体分子的全球许可协议。根据协议条款，百济神州将向百奥赛图支付首付款。关于百济神州百济神州是一家注册地位于瑞士的全球肿瘤治疗创新公司，专注于为全世界的癌症患者研发创新抗肿瘤药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710080113a6a041c4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710080113a6a041c4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1500","BK1161","LU0588546209.SGD","06160","LU1969619763.USD","02315","BK1574","688235","BK1583","LU2328871848.SGD","BK1588","06978","ONC","LU0307460666.USD"],"gpt_icon":0},{"id":"2550502024","title":"百奧賽圖-B盤中異動 急速上漲5.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2550502024","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550502024?lang=zh_tw&edition=fundamental","pubTime":"2025-07-09 13:41","pubTimestamp":1752039668,"startTime":"0","endTime":"0","summary":"2025年07月09日下午盘13时41分，百奥赛图-B股票出现波动，股价快速拉升5.33%。百奥赛图-B股票所在的生物技术行业中，整体涨幅为1.85%。百奥赛图-B公司简介：北京百奥赛图基因生物技术有限公司是一家主要从事药物开发业务及临床前研究中国公司。2024年，当百奥赛图在财报中高调宣布“阶段性扭亏为盈”时，董事长沈月雷的薪酬从205万元飙升至425.9万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709134109a43f8cde&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709134109a43f8cde&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02315","BK1161"],"gpt_icon":0},{"id":"2550506386","title":"百奧賽圖IPO：18億虧損下的高管薪酬狂歡與研發斷崖","url":"https://stock-news.laohu8.com/highlight/detail?id=2550506386","media":"中金在线","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550506386?lang=zh_tw&edition=fundamental","pubTime":"2025-07-09 10:40","pubTimestamp":1752028839,"startTime":"0","endTime":"0","summary":"一家累计亏损18亿元的 生物医药 企业，高管年薪却集体突破200万元，研发投入腰斩的同时，实控人薪酬翻倍。2024年，当百奥赛图在财报中高调宣布“阶段性扭亏为盈”时，董事长沈月雷的薪酬从205万元飙升至425.9万元。一边是累计未弥补亏损高达18.4亿元的财务黑洞，一边是高管薪酬逆势暴涨的狂欢。百奥赛图的资金链已紧绷到临界点。此次IPO募资缩水7亿元后，11.85亿元的募资额更像是杯水车薪。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709105044a43f3e8e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709105044a43f3e8e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02315","BK1161"],"gpt_icon":0},{"id":"2549560522","title":"70%海外收入含金量：百奧賽圖進入全球化價值兑現期","url":"https://stock-news.laohu8.com/highlight/detail?id=2549560522","media":"Ofweek光电信息网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549560522?lang=zh_tw&edition=fundamental","pubTime":"2025-07-08 09:48","pubTimestamp":1751939280,"startTime":"0","endTime":"0","summary":"百奥赛图并不是一家靠单一管线博弈临床成功率的Biotech公司。从2024年财报来看，百奥赛图实现了自2021年以来的首次年度盈利，全年净利润达3354万元，顺利实现扭亏为盈，标志着公司正式进入良性增长通道。其中，抗体业务线收入同比大幅增长80.7%，展现出其核心平台的商业转化能力。百奥赛图正以中国原创的平台，构建一张通向全球的新药地图。对于关注长期价值的投资者而言，百奥赛图不是投机故事，而是一个等待被价值发现的真实平台。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708095509953a3a7c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708095509953a3a7c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02315"],"gpt_icon":0},{"id":"2549392255","title":"誰能為全球創新藥提供真正的「源頭動力」？","url":"https://stock-news.laohu8.com/highlight/detail?id=2549392255","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549392255?lang=zh_tw&edition=fundamental","pubTime":"2025-07-07 19:05","pubTimestamp":1751886339,"startTime":"0","endTime":"0","summary":"在此背景下，一个问题正在被越来越多药企、投资人和科研机构反复追问：中国是否具备能够真正为全球创新药提供“源头动力”的平台型企业？最后是全球专利护航。特别是RenTCR-mimic小鼠，通过HLA人源化与免疫pHLA复合物，成功打通了“抗体识别胞内抗原”这一全新靶点空间，为抗体进入传统“不可成药”靶点提供可能。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707191357953979be&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707191357953979be&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06978","BK1161","BK1574","02315"],"gpt_icon":0},{"id":"2549303773","title":"百奧賽圖-B盤中異動 早盤股價大跌5.22%報21.800港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2549303773","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549303773?lang=zh_tw&edition=fundamental","pubTime":"2025-07-07 10:09","pubTimestamp":1751854163,"startTime":"0","endTime":"0","summary":"2025年07月07日早盘10时09分，百奥赛图-B股票出现异动，股价大幅跳水5.22%。截至发稿，该股报21.800港元/股，成交量1.65万股，换手率0.01%，振幅3.91%。资金方面，该股资金流入6.7075万港元，流出24.495万港元。百奥赛图-B股票所在的生物技术行业中，整体跌幅为1.03%。其相关个股中，正大企业国际、思路迪医药股份、创胜集团-B涨幅较大，振幅较大的相关个股有北海康成-B、正大企业国际、药捷安康-B，振幅分别为20.29%、11.37%、10.31%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707100924979c7918&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707100924979c7918&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02315","BK1161"],"gpt_icon":0},{"id":"2549371410","title":"百奧賽圖-B(02315.HK)獲LAKE BLEU CAPITAL (Hong Kong)增持8.15萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2549371410","media":"格隆汇","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549371410?lang=zh_tw&edition=fundamental","pubTime":"2025-07-07 06:54","pubTimestamp":1751842447,"startTime":"0","endTime":"0","summary":"格隆汇7月7日丨根据联交所最新权益披露资料显示，2025年7月3日，百奥赛图-B(02315.HK)获LAKE BLEU CAPITAL (Hong Kong) LIMITED在场内以每股均价23.392港元增持8.15万股，涉资约190.64万港元。增持后，LAKE BLEU CAPITAL (Hong Kong) LIMITED最新持股数目为561.16万股，持股比例由4.99%上升至5.07%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/07/07065451518670.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","IE00B7SZL793.SGD","IE00B19Z4B17.USD","IE00B66KJ199.SGD","BK4202","IE0031619046.USD","LAKE","BLEU","02315","BK4568"],"gpt_icon":0},{"id":"2548393299","title":"LAKE BLEU CAPITAL (Hong Kong) LIMITED增持百奧賽圖(02315)8.15萬股 每股作價約23.39港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2548393299","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548393299?lang=zh_tw&edition=fundamental","pubTime":"2025-07-04 19:05","pubTimestamp":1751627103,"startTime":"0","endTime":"0","summary":"7月3日，LAKE BLEU CAPITAL (Hong Kong) LIMITED增持百奥赛图(02315)8.15万股，平均每股作价为23.392港元，总金额约为190.64万港元。","market":"fut","thumbnail":"https://img.zhitongcaijing.com/image/20250704/20250704190513_61183.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20250704/20250704190513_61183.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1314177.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4202","BK1161","IE00B19Z4B17.USD","02315","IE00B7SZL793.SGD","BLEU","LAKE","BK4568","IE0031619046.USD","IE00B66KJ199.SGD"],"gpt_icon":0},{"id":"2548332728","title":"百奧賽圖-B盤中異動 快速下跌5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2548332728","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548332728?lang=zh_tw&edition=fundamental","pubTime":"2025-07-04 10:03","pubTimestamp":1751594622,"startTime":"0","endTime":"0","summary":"2025年07月04日早盘10时03分，百奥赛图-B股票出现波动，股价大幅跳水5.08%。截至发稿，该股报22.400港元/股，成交量12.1万股，换手率0.11%，振幅3.60%。百奥赛图-B股票所在的生物技术行业中，整体涨幅为0.41%。百奥赛图-B公司简介：北京百奥赛图基因生物技术有限公司是一家主要从事药物开发业务及临床前研究中国公司。同时，公司正在业绩波动、研发投入持续萎缩及与百奥赛图的专利纠纷渐入关键阶段的多重挑战中寻找平衡。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704100343a4ce6503&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704100343a4ce6503&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02315","BK1161"],"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":6,"totalSize":155,"code":"91000000","status":"200"}]}}